IMNM vs. IGMS, VIR, AIMT, CRNX, AXSM, RARE, MRUS, HCM, CORT, and PBH
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include IGM Biosciences (IGMS), Vir Biotechnology (VIR), Aimmune Therapeutics (AIMT), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), Ultragenyx Pharmaceutical (RARE), Merus (MRUS), HUTCHMED (HCM), Corcept Therapeutics (CORT), and Prestige Consumer Healthcare (PBH). These companies are all part of the "medical" sector.
IGM Biosciences (NASDAQ:IGMS) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.
42.8% of IGM Biosciences shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 57.0% of IGM Biosciences shares are held by company insiders. Comparatively, 8.6% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Immunome has higher revenue and earnings than IGM Biosciences. Immunome is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
IGM Biosciences currently has a consensus price target of $17.89, suggesting a potential upside of 114.75%. Immunome has a consensus price target of $29.80, suggesting a potential upside of 99.46%. Given Immunome's higher possible upside, equities research analysts clearly believe IGM Biosciences is more favorable than Immunome.
Immunome has a net margin of -1,829.44% compared to Immunome's net margin of -11,255.25%. IGM Biosciences' return on equity of -37.33% beat Immunome's return on equity.
In the previous week, IGM Biosciences had 2 more articles in the media than Immunome. MarketBeat recorded 6 mentions for IGM Biosciences and 4 mentions for Immunome. IGM Biosciences' average media sentiment score of 1.21 beat Immunome's score of 0.65 indicating that Immunome is being referred to more favorably in the news media.
IGM Biosciences received 38 more outperform votes than Immunome when rated by MarketBeat users. However, 69.44% of users gave Immunome an outperform vote while only 48.84% of users gave IGM Biosciences an outperform vote.
IGM Biosciences has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.
Summary
Immunome beats IGM Biosciences on 11 of the 18 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
